Chief Regulatory, Quality & Compliance Officer

Consultant

Senior Vice President, Global Regulatory Affairs

Therapeutic Area Lead, Global Regulatory Affairs, Rare Disease

Sr. Director, Regulatory Affairs

Sr. Advisor, Global Regulatory Affairs

Sr Advisor, Translational Med

Sunil Kadam

Apollo Therapeutics

Chief Executive Officer

Active military duty (UK gov pandemic response, including as member of Vaccines Task Force)

Head of Johnson & Johnson Innovation, EMEA

Chief Executive Officer at Apollo Therapeutics

Richard Mason

Chief Medical Officer

Senior Vice President Clinical Development

Executive Medical Director

Snr Medical Director

Chief Medical Officer at Apollo Therapeutics.

Sanjay Aggarwal

Chief Scientific Officer

Senior Director, Research Project Leader, Clinical Research

Research Fellow, Research Project Leader, Biology

Safety Development Leader

Chief Scientific Officer at Apollo Therapeutics

Richard Butt

Chief Business Officer

Commercialization, BTG Pulmonology

Business Development

Strategic Partnerships

Investor - Healthcare

Investor - Public and Private Healthcare

Equity Research

Chief Business Officer at Apollo Therapeutics

Arjun Krishnan

Chief Financial Officer

Chief Development Officer

Managing Director

Partner

Director

Associate

Chief Financial Officer at Apollo Therapeutics

Jamie Heath

Finance Business Partner

Deal Transition Finance Analyst

Financial Controller

Finance Manager

Assistant Accountant

Accounts Payable Executive

Temporary Accounts Assistant

Juan H.

FP&A Business Partner

Financial Reporting Manager

Supply Chain Finance Manager

Group Accountant

Internal Audit Manager

Audit Executive

Gemma Bishop

Head Of Finance

Finance director

Head of Financial Planning and Analysis

Assistant Corporate Controller

Manager

Experienced, ACA qualified senior finance professional. Passionate about building and supporting high performing teams which enable efficient data driven decision making across a business.

Gary Collins

Head of Program and Portfolio Strategy

Associate Director, Tumour Strategy, Melanoma & NSCLC

Associate Director, Portfolio Strategy and Competitive Intelligence

Senior Manager, Portfolio Strategy and Competitive Intelligence

Equity Research Analyst (Healthcare)

Healthcare (Biotech) Associate Director

Healthcare (Biotech) Associate Analyst

PhD in Biotechnology and Biosensors with a  focus on Diabetes

Mres Of Chemical Biology Of Health And Disease

Nanotechnology Degree

Head of Program and Portfolio Strategy at Apollo Therapeutics

Daniel Wilkinson

Head of Program Management

Project Manager

Development Director

Research Project Leader

Process Chemist

Head of Program Management, Apollo Therapeutics

Charlotte Lane

Head of IT

Head of IT (Interim)

MD and Performance Coach

Life Sciences Fractional IT Director and MD

Senior Director, IT Operations

Global IT Infrastructure and Operation Associate Director and Senior IT Manager

Infrastructure Solutions Architect

Associate Manager

Senior Analyst I

UK and Research IT Server and Network Support Engineer

IT Support Engineer

Infrastructure Consultant

Trainee Technicial

Head of IT | Coach | Speaker | Average CrossFitter

Jeremy Cooper

Director Clinical Operations

Clinical Project Manager

Associate Clinical Project Manager

In-House Clinical Research Associate

Clinical Research Associate

Public school teacher

Certified Personal Trainer

Clinical Operations Leader

Laurie Green

Associate Director, Program & Portfolio Strategy

Senior Consultant, Healthcare Strategy Consulting

Consultant, Healthcare Strategy Consulting

Pharma/Biotech Equity Research

PhD Student and Postdoctoral Researcher

Teaching Supervisor

Teaching Assistant

Healthcare Strategy

Martin Michel

Director - Business Development

Senior Manager - Corporate Development

Analyst - Corporate Development

Innovation Fellow

Senior Consultant - Life Sciences

Consultant - Office of Strategy Management

Blavatnik Associate

Senior Investigator - Project Lead

Postdoctoral Research Scientist

Colin Wilson

Director, Development Project Manager

Senior Manager, Portfolio and Program Management

Project Manager Principal

Senior Project Coordinator

Program Manager (Portfolio and Lifecycle Management)

Associate Program Manager

Project Coordinator

Bonnie Petka

Director of CMC

Associate Director CMC, Drug Product

Formulation Developability and CMC technical leader

Drug Delivery Leader

Senior Principal Scientist

IDC Scientist

VP, Head of CMC at Apollo Therapeutics

Neil Flanagan

Sr. Director, Clinical Scientist

Sr. Director, R&D Strategy

Vice President, Strategy and Program Leadership

Director, Rare Diseases, Early Clinical Development

Clinical Trial Leader

Engineer II

Sr. Director, Clinical Scientist at Apollo Therapeutics

Matthew Cardinal

Director, Chemistry and Research Operations

Chemistry Project Manager

Consultant Project Manager

Research scientist 2

Research Scientist

Senior Research Associate

Director, Chemistry and Research Operations at Apollo Therapeutics

Susanne Wright

Drug Discovery Program Director

Nadine Clemo

Apollo Therapeutics is a portfolio biotech company that develops a broad range of drug programs to generate value for its stakeholders. It has a diversified clinical-stage portfolio of assets focused on high-value markets, with over 20 programs in its core areas of biological focus, including cell signaling, cell stress response, and immunology.

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. 

Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners.

Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. 

For more information, please visit our website at www.apollotherapeutics.com

UCLB

Rock Springs Capital

Patient Square Capital

M&G Plc

Reimagined Ventures

UCL Technology Fund

Our CEO Richard Mason will be presenting an overview of Apollo Therapeutics at the Evercore ISI 2024 Emerging Biotech Conference tomorrow (Thursday, February 29) at 10:45 – 11:15 ET.
#biotech  #conference 


Apollo Therapeutics will be attending the Cowen Inc. 44th Annual Health Care Conference in Boston, US next week from March 4-6. Our CEO Richard Mason and CFO Jamie Heath will be hosting one-on-one meetings on Tuesday, March 5 - meeting slots can be booked via Cowen or please do let us know directly if you would like to connect at the conference.
 
We look forward to seeing you there!
 #biotech #conference 


We are delighted to have completed the second close of our Series C financing in December 2023, bringing the total raised in this round by the Company to $260m. 
 
The Series C financing was led by Patient Square Capital and included participation by multiple new investors including M&G plc and two of the largest US public pension plans, along with existing investors including Rock Springs Capital.
 
This fundraise means we can continue to progress our broad and diversified pipeline of over 20 uncorrelated therapeutic programs, with multiple assets about to enter the clinic in early 2024.
	 
#seriesc #biotech #fundraising 

Photo	Title	Links
	Sunil Kadam Chief Regulatory, Quality & Compliance Officer
	Richard Mason Chief Executive Officer
	Sanjay Aggarwal Chief Medical Officer
	Richard Butt Chief Scientific Officer
	Arjun Krishnan Chief Business Officer
	Jamie Heath Chief Financial Officer
	Juan H. Finance Business Partner
	Gemma Bishop FP&A Business Partner
	Gary Collins Head Of Finance
	Daniel Wilkinson Head of Program and Portfolio Strategy
	Charlotte Lane Head of Program Management
	Jeremy Cooper Head of IT
	Laurie Green Director Clinical Operations
	Martin Michel Associate Director, Program & Portfolio Strategy
	Colin Wilson Director - Business Development
	Bonnie Petka Director, Development Project Manager
	Neil Flanagan Director of CMC
	Matthew Cardinal Sr. Director, Clinical Scientist
	Susanne Wright Director, Chemistry and Research Operations
	Nadine Clemo Drug Discovery Program Director

COM:APOLLOTHERAPEUTICS